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ABSTRACT 
 
Scrapie is a lethal, degenerative sickness that influences the sensory systems of 
sheep and goats. Creutzfeldt-Jakob infection is a degenerative neurological issue 
that is serious and constantly lethal in human. Both the maladies are brought about 
by a protein called prion. The transformation of the α-helical, cell isoform of the 
prion protein (Prp
c) to the insoluble, β-sheet rich irresistible, infection creating 
isoform (PrP
sc
) is the key occasion in prion illness. I have discovered two prion 
proteins on which the inhibitors could be docked. They are 1XYU (sheep) and 
1FO7(human). I have additionally searched for different inhibitors which might be 
utilized to tie with the dynamic locales of the two proteins. Some of them are 
tannin, quinacrine, astemizole, terfenadine, lovastatin, amantadine, acyclovir, 
clonazepam, pentosan polysulfate, perk inhibitors, rivastigmine,etc. 
 
KEYWORDS: Prion, 1XYU, tannin, quinacrine, 1FO7, acyclovir, 
clonazepam, perk inhibitors, rivastigmine. 
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1.1 INTRODUCTION 
 
Scrapie is a deadly, degenerative disease which attacks the nervous system of 
sheep and goats. It is a type of Transmissible Spongiform Encephalopathies 
(TSEs), also related to Bovine Spongiform Encephalopathies (BSEs or ―mad cow 
disease‖) and chronic wasting disease of deer. A protein named PRION causes 
Spongiform Encephalopathies which include Scrapie disease. 
                                        The disease apparently causes an itching sensation in 
animals. The traits of this disease are: 
 Excessive lip smacking 
 Altered gaits 
 Convulsive collapse 
It is transmissible and infectious among similar animals. So the best way to contain 
it is to quarantine or destroy those affected. However it tends to continue in flocks 
and can also arise apparently spontaneously in flocks that have not previously had 
cases of the disease. It usually affects sheep around 3 to 5 years of age. This 
appears due to transmission at the time of birth or from contact with placental 
tissues.  
         Scrapie is not found to be infecting humans. The mechanism of transmission 
between animals and other aspects of the biology of the disease are poorly 
understood and these are active areas of research. Scrapie is associated with 
modification of normal Prion protein to a misfolded abnormal protein, which 
accumulates in amyloid plaques in lymphoreticular and nervous tissues. 
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CREUTZFELDT-JAKOB DISEASE is a degenerative neurological disorder 
which is not curable and has a high mortal rate. It is also known as the human 
version of mad cow disease even though classic CJD can’t be compared to bovine 
spongiform encephalopathy. The disease is caused by a protein named Prion. 
Prions are misfolded proteins which replicates by the conversion of properly folded 
counterparts in their hosts, to the same misfolded structure they possess. The 
disease leads to rapid neurodegeneration, causing the brain tissue to develop holes 
and eventually forming a sponge like texture.  
 SYMPTOMS:   The initial symptoms of CJD are rapidly progressive dementia, 
causing memory loss, hallucinations and personality changes. Other symptoms 
include depression, obsessive-compulsive symptoms, paranoia, anxiety and 
psychosis, which are accompanied by problems with speech impairment, jerky 
movements, balance and coordination disfunction. Most victims are observed to 
die within six months of the appearance of initial symptoms, mainly due to 
impaired coughing reflexes caused by pneumonia. The symptoms of CJD are 
caused by the progressive death of brain’s nerve cells, which is associated with the 
growth of abnormal Prion proteins forming amyloids. When brain tissue (of a 
patient suffering from CJD) is observed under microscope, many tiny holes are 
visible due to the death of nerve cells. The structure of the tissue is more of a 
sponge like structure. The word ―spongiform‖ in TSE refers to the sponge like 
appearance of brain tissue. 
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1.2 CAUSE OF THE DISEASES 
PRION PROTEIN: Prions are small proteinaceous particles that resist 
inactivation by procedures known to modify nucleic acids. The abnormal prion 
protein that forms in animals with Scrapie is resistant to denaturing agents, heat 
and proteinase K digestion. The abnormal Prion protein does not fulfill Koch’s 
postulates and it has been postulated that abnormal Prion protein is a pathological 
response to infection rather than the causal agent. Variations in the prion protein 
gene result in differing susceptibilities or resistance to Prion and thus to natural and 
experimental Scrapie[16]. 
 In sheep, all except one of the 15 known Prion protein genotypes are known 
to have some susceptibility to classical Scrapie and some are known to be 
also susceptible to BSE. The only exception is the homozygous ARR 
genotype 
 In goat, Prion protein is expressed from a single gene, which appears>99% 
homologous to that of sheep, but goats do not share the Scrapie modulation 
polymorphisms present in the sheep. Analysis of the caprine Prion protein 
gene has revealed several different alleles. Four prion protein variants have 
been described in British goats, three of them are goat specific with single 
amino acid changes at codon 142, 143, 240. The amino acid changes 
associated with Scrapie susceptibility of sheep, i.e. Val at codon 136 have 
not been described in goats[18]. 
The Prion that is believed to cause Creutzfeldt-Jakob exhibits at least two stable 
conformations. One, the native state, is water soluble and present in healthy cells. 
The other conformational state is relatively water insoluble and readily forms 
protein aggregates. The CJD Prions are dangerous because it promotes refolding of 
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native proteins into the diseased state. The number of misfolded protein molecules 
will increase exponentially and the process leads to a large quantity of insoluble 
protein in affected cells. This mass of misfolded proteins disrupts cell function and 
causes cell death. Mutations in the gene for the Prion protein can cause a 
misfolding of the dominantly alpha-helical regions into beta-pleated sheets. This 
change in conformation disables the ability of the protein to undergo digestion.      
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1.3 LITERATURE REVIEW 
The change of the α-helical, cell isoform of the prion protein (Prpc) to 
the insoluble, β-sheet-rich, irresistible, illness-creating isoform (Prpsc) is the key 
occasion in prion illnesses. In a prior study, a few manifestations of Prp were 
changed over into a fibrillar state by utilizing an as a part of vitro change 
framework comprising of low centralizations of SDS and 250 mm Nacl. Here, we 
portray the structure of the fibril antecedent state, that is, the solvent state under 
fibrillization conditions.. Exponential, seed-improved development might be 
attained in homogeneous result, which could be upgraded by sonication. From 
these information, we propose an unthinking model of fibrillization, including the 
vicinity of a few halfway structures.[1] 
Requested protein collection in the cerebrum is a sign of Alzheimer's 
illness and scrapie. The illness-particular amyloid fibrils involve basically a 
solitary protein, amyloid beta, in Alzheimer's infection, and the prion protein in 
scrapie. These proteins might be prompted to structure totals in vitro that are 
unclear from cerebrum-determined fibrils. Hence, much exertion has been put 
resources into the improvement of in vitro model frameworks to study the subtle 
elements of the total methodologies and the impacts of endogenous atoms that 
have been involved in malady Moreover, amyloid shaping could be seeded by a 
preformed fibril. The physiological results of this system are examined.[2] 
Location of Prpsc protein and Prp heredity of the transmission of BSE 
to sheep and goats, with the impacts of the transmission of common scrapie from a 
cerebrum homogenate from a solitary sheep. After intracerebral and oral 
immunizations there were similitudes in the clinical signs because of the two 
wellsprings of contamination, yet there were contrasts in pathology at the end 
phase of sickness and in the genotypes of the sheep which succumbed to the 
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difficulties. The hatching time of BSE was connected with the sheep Prp codon 
171 genotype, yet the common scrapie source, notwithstanding affecting sickness 
just in known defenseless genotypes, demonstrated no reasonable affiliation with 
Prp genotype.[3][4] 
Throughout the time between contamination and the appearance of the 
clinical side effects, moment measures of Prpsc imitate by change of host Prpc, 
producing a lot of Prpsc totals in the brains of unhealthy people. We intended to 
recreate this occasion in vitro. Here we report a methodology including cyclic 
enhancement of protein misfolding that permits a fast change of vast 
overabundance Prpc into a protease-safe, Prpsc-like structure in the vicinity of 
moment amounts of Prpsc layout. In this technique, adroitly closely resembling 
polymerase chain response cycling, totals shaped when Prpsc is brooded with Prpc 
are upset by sonication to create numerous littler units for the proceeded 
development of new Prpsc. After cyclic intensification more than 97% of the 
protease-safe Prp show in the specimen relates to recently changed over protein.[5] 
In late studies, the amyloid manifestation of recombinant prion protein 
(Prp) enveloping buildups, processed in vitro actuated transmissible prion infection 
in mice. These studies indicated that dissimilar to "traditional" Prpsc handled in 
vivo, the amyloid fibrils produced in vitro were more proteinase-K touchy. Here 
we show that the amyloid structure holds a proteinase K-safe center made just out 
of buildups. The PK-safe parts of the amyloid structure are like those saw upon PK 
assimilation of a minor subpopulation of Prpsc as of late distinguished in patients 
with sporadic Creutzfeldt-Jakob ailment (CJD). Surprisingly, this center is 
sufficient for multiplying toward oneself movement in vitro and jam a β-sheet-rich 
fibrillar structure. Full-length recombinant Prp, on the other hand, creates two 
subpopulations of amyloid in vitro: One is like the minor subpopulation of Prpsc, 
and the other to established.[6]. 
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We distinguish porphyrins and phthalocyanines as inhibitors of Prp-
res aggregation. The most intense of these tetrapyrroles had Ic50 qualities of 0.5–1 
μm in scrapie-contaminated mouse neuroblastoma (Scnb) cell societies. Hindrance 
was seen without impacts on protein biosynthesis when all is said in done or Prp-
sen biosynthesis specifically. Tetrapyrroles likewise repressed Prp-res structuring 
in a without phone response made overwhelmingly out of hamster Prp-res and Prp-
sen. Inhibitors were found around phthalocyanines, deuteroporphyrins IX, and 
meso-substituted porphines; cases included mixes holding anionic, impartial protic, 
and cationic fringe substituents and different metals.[7][8] 
Ox-like spongiform encephalopathy (BSE) and its human 
proportional, variant Creutzfeldt–jakob infection (vcjd), are created by the same 
strain of irresistible operator, which is like, however unique from, >20 strains of 
their sheep scrapie homologue. A finer understanding of the sub-atomic strain 
determinants could be gotten from cells in monoculture than from entire creature 
studies where diverse cell focusing on is normally a strain-related characteristic. 
Despite the fact that a couple of cell sorts could be contaminated with distinctive 
strains, the phenotypes of the new strains have not been mulled over.[9] 
Prion maladies, including scrapie, are hopeless neurodegenerative 
issue. A few mixes can postpone illness after a fringe scrapie vaccination, however 
few are powerful against cutting edge infection. Here, we tried different related 
porphyrins, yet just Fe(iii)meso-tetra(4-sulfonatophenyl)porphine infused into 
mouse brains after intracerebral scrapie immunization generously expanded 
survival times.[8] 
We indicate that rabbit Prp-sen does not structure Prp-res in murine 
tissue society cells tirelessly tainted with the mouse-adjusted scrapie operator. 
Dissimilar to other TSE species hindrances that have been considered, 
discriminating amino corrosive deposits that restrain Prp-res framing are spotted 
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all around the rabbit Prp arrangement. Our outcomes recommend that the safety of 
rabbits to contamination by the TSE executor is because of numerous rabbit Prp-
particular amino corrosive buildups that bring about a Prp structure that is unable 
to refold to the anomalous isoform connected with infection.[10] 
MECHANISM: The transformation of the α-helical, cell isoform of the prion 
protein (PrP
c) to the insoluble, β-sheet rich irresistible, malady creating isoform 
(PrP
sc
) is the key occasion in prion infection. In a prior study, a few types of PrP
c
 
changing over to PrP
sc
 causes Prion replication.[1][17][19]  
 Several unthinking models have been proposed for this change of adaptation, 
which are  
   •heterodimer model    • the cooperative model    • the model of seeded 
polymerization 
 
 
 
Figure 1.1:Mechanism : (A)A 
proposed model depicts the 
preamyloid state in a monomer 
dimer equilibrium, stationary state 
of trimer, stable nucleus of two 
trimers and growing 
fibril.(B)Reaction scheme of seeded 
fibrillization. D=degradation, 
E=seed dependent growth, 
B=breakage of fibrils, λ= synthesis, 
δ= degradation of monomeric PrP 
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CHAPTER 2 
SOURCES OF PRION 
PROTEIN 
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2.1 Ovis aries 
We go to the site www.rcsb.org and look for Prion protein and keeping scientific 
classification as Ovis aries. At that point we get a rundown of PDB Ids. From the 
schedule I haphazardly pick a protein which is:  
1XYU:  The NMR structures if the recombinant cell type of the Prion proteins 
(PrP
c
) of the feline, canine and pig and of two polymorphic types of prion protein 
from sheep are exhibited. In these species, PrP
c
 comprises of N-terminal adaptably 
amplified tail with roughly 100 amino corrosive deposits and a C-terminal globular 
area of more or less 100 buildups with three alpha-helices and a short antiparallel 
beta-sheet. In spite of the fact that this worldwide structural engineering 
corresponds with at one time reported murine, Syrian hamster, ox-like and human 
PrP
c
 structures, there are nearby contrasts between the globular space of diverse 
species. Since the five recently decided PrP
c
 structure start from species with 
broadly distinctive transmissible spongiform encephalopathy records, the present 
information demonstrate long ago uncharacterized conceivable associations 
between neighborhood offers in PrP
c
 3-D structures and powerlessness of diverse 
mammalian species to transmissible spongiform encephalopathy. 
RELATED STRUCTURES: 
 1XYJ 
 1XYK 
 1XYQ 
 1Y2S 
 
 
 
                                                                                 Figure 2.1: 1XYU 
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2.2 Homo sapiens 
 
1FO7  Human prion protein mutant E200k Fragment 90-231 prion engendering in 
TSE s includes the transformation of cell protein PrP
c
 into a pathogenic conformer 
PrP
sc
. Heredity types of the sickness are connected to particular transformations in 
the gene coding for the prion protein. To increase understanding into the atomic 
premise of these issue, the result structure of the familial CJD identified with E 
200k variant of human prion protein was dictated by multi-dimensional atomic 
attractive thunder spectroscopy. Exceptionally, separated from minor contrasts in 
adaptable districts, the spine tertiary structure of the E200k variant is almost 
indistinguishable to that reported for the wild sort human prion protein. The main 
real result of the transformation is the bother of surface electrostatic potential. The 
present structural information positively propose that protein surface locates 
prompting variations from the norm in the collaboration of prion protein with 
auxillary proteins/chaperones or cell layers ought to be viewed as key parts of a 
spontaneous PrP
cPrPsc change in the E200k type of genetic prion ailment.[14] 
RELATED STRUCTURES: 
1FKC: It assumes a part in neuronal improvement and synaptic pliancy. It may be 
needed for neuronal myelin sheath support. May assume a part in iron uptake and 
iron homeostasis. Dissolvable oligomers are harmful to cosmopolitan 
neuroblastoma cells and actuate apoptosis (in vitro). Acquaintanceship with Gpc1 
(by means of its heparin sulfate chains) targets PRNP to lipid pontoons. Likewise 
gives Cu
2+
 or Zn
2+
 to the ascorbate-intervened Gpc1 deaminase debasement of its 
heparin sulfate side chains. 
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Figure 2.2:1FO7 
 
 
 
 
                                                   Figure 2.3: 1FKC 
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CHAPTER 3 
MOLECULAR DOCKING 
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3.1 IMPORTANT ASCPECTS OF MOLECULAR 
DOCKING 
 
Molecular docking is a broadly utilized computational instrument for the 
investigation of sub-atomic distinguishment, which intends to anticipate the 
coupling mode and tying partiality of a complex shaped by two or more constituent 
atoms with known structures.  
 
Goals:  
• to check whether two atoms collaborate with one another( (fitting 
introduction).  
• whether introduction that boosts collaboration or minimizes absolute vitality 
of the complex.  
 
 TYPES OF MOLECULAR DOCKING:  
• receptor - -LIGAND  
• enzyme - -SUBSTRATE  
• protein - -PROTEIN  
• protein-  -DNA/RNA  
 
  
PROTEIN-PROTEIN DOCKING:   
• both atoms are inflexible  
• steric imperatives to cutoff pursuit space and inspect energetics of tying 
conformities.  
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 PROTEIN-LIGAND DOCKING:  
• flexible ligand, unbending receptor  
• search space much bigger  
• either diminish adaptable ligand to inflexible pieces joined by one or more 
pivots or pursuit the conformational space utilizing atomic progress.  
 
 FACTORS AFFECTING MOLECULAR DOCKING:  
• intermolecular strengths—covalent powers  
• bond lengths  
• bond edges  
• dihedral edges  
• electrostatic strengths, dipole-dipole collaborations  
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3.2 ACTIVE SITE PREDICTION 
 
 Use of Q-site finder  we open the site www.modelling.leeds.ac.uk/qsitefinder. 
We then hunt down obliged tying destinations of proteins and DNAs are frequently 
connected with structural cavities and pockets. After that from the right hand side 
we pick the rundown of dynamic destinations which are found as outcome.  
 
 We can also find the active site of Protein by going to the site http://sts-
fw.bioengr.uic.edu/castp/calculation.php . There we can upload or .pdb files 
and predict the active binfing site. 
The active sites of 1XYU and 1FO7 are: 
Figure 3.0: Active sites of 1XYU and 1FO7 as predicted in CASTP 
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3.3 STEPS INVOLVED IN DOCKING 
 First we download the protein files from the site www.rcsb.org . 
 Then we download the inhibitors from www.drugbank.ca  in .mol format. 
 Next we open the file in Chimera (version 1.8) software and convert the 
protein files as well as the inhibitors into .pdb. 
 Then we open the .pdb file in Autodock tools (version 1.5.6) software. 
 Next we add hydrogen to the molecule (polar only). 
 Next we go to gridmacromoleculechoosesave as .pdbqt file 
  Next we click on grid again and then click on grid box. 
 Then we set the desired values in grid box . 
 Next for the ligand we click on ligandinputopenopen the 
inhibitors.pdb file. 
 Next we go to ligandtorsion treechoose torsionsdone. 
 Next we click ligandtorsion treedetect root. 
 Next we save the file by ligandoutputsave as .pdbqt. 
 Next we create a folder name ―config‖ and put all the .pdbqt files in it.  
 In the config folder we create two new text files by the name conf.txt and 
log.txt 
 In conf.txt we write:   
     receptor = receptor.pdbqt 
     ligand = ligand.pdbqt 
 
out = all.pdbqt 
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center_x = ____                                                                                                                                                      
center_y = ____        
center_z = ____    
 
size_x = ____ 
size_y = ____ 
size_z = ____ 
 
 Then we enter the desired values. 
 Then we open cmd and run autodock vina by typing 
C:\config_folder_path>‖C:\Program Files\The Scripps Research 
Institute\Vina\vina.exe‖ –config conf.txt –log log.txt 
And then we press enter 
 We get the output stored in log.txt file. 
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3.4 INHIBITORS USED FOR DOCKING 
Given below are the Pymol visualization of various inhibitors which are used in the 
docking process of 1XYU and 1FO7: 
Fig 3.1:QUINACRINE (DB01103)            Fig 3.2: ASTEMIZOLE  (DB00637) 
Fig 3.3: ACYCLOVIR(DB00787)                   Fig 3.4 TERFENADINE (DB00342)                       
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Fig 3.5:LOVASTATIN    (DB00227)            Fig 3.6: AMANTADINE  (DB00915) 
 
Fig 3.7:CLONAZEPAM  (DB01068)                        Fig 3.8: PENTOSAN 
POLYSULFATE                                          
(DB00686) 
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Fig 3.9:PROMETHAZINE (DB01069)                   Fig 3.10:  PERK INHIBITORS 
 
Fig 3.11/:2-(2-benzimidazolyl)-5-[4 
-(2-imidazolino)phenyl]furan                        Fig 3.12 GALANTAMINE(DB00674) 
dihydrochloride (DB00772) 
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Fig 3.13:RIVASTIGMINE (DB00989)           Fig 3.14:MEMANTINE (DB 01043) 
                          
Fig 3.15:TACRINE (DB00382)               Fig 3.16:PORPHYRIN Fe(iii) (DB01710) 
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Fig 3.17:AMINOTHIAZOLINE (DB02335) 
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3.5 DOCKING RESULTS  
 
Table A: Binding energy results obtained on docking  (1XYU) with several 
inhibitors. 
SL 
NO. 
Name of the compound Drug bank 
ID 
Structure Binding 
Energy 
(Kcal/mol) 
1 QUINACRINE (DB01103)  -9.4 
2 ASTEMIZOLE DB00637  -7.1 
3 TERFENADINE DB00342 
 
-9.6 
4 LOVASTATIN DB00227  -11.9 
26 
 
5 AMANTADINE DB00915  -7.6 
6 CLONAZEPAM DB01068 
 
-9.7 
7 PENTOSAN 
POLYSULFATE 
DB00686 
 
-11.4 
8 PROMETHAZINE DB01069 
 
-9.6 
9 PERK INHIBITORS   -12.9 
27 
 
10 2-(2-benzimidazolyl)-5-[4-
(2-
imidazolino)phenyl]furan 
dihydrochloride 
DB00778 
 
-8.5 
11 GALANTAMINE DB00674 
 
-8.3 
12 RIVASTIGMINE DB00989 
 
-9.5 
13 MEMANTINE DB01043  -8.2 
14 TACRINE DB00382 
 
-8.5 
28 
 
15 PORPHYRIN Fe(iii) DB00382  -6.9 
16 AMINOTHIAZOLINE DB02335 
 
-2.7 
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Table B: Binding energy results obtained on docking   (1FO7)  with several 
inhibitors. 
SL 
NO. 
Name of the compound Drug bank 
ID 
Structure Binding 
Energy 
(kcal/mol) 
1 QUINACRINE (DB01103)  -8.6 
2 ASTEMIZOLE DB00637  -9.5 
3 TERFENADINE DB00342 
 
-9.4 
4 LOVASTATIN DB00227  -9.3 
5 AMANTADINE DB00915  -5.5 
30 
 
6 CLONAZEPAM DB01068 
 
-6.2 
7 PENTOSAN 
POLYSULFATE 
DB00686 
 
-8.2 
8 PROMETHAZINE DB01069 
 
-7.1 
9 PERK INHIBITORS   -8.5 
10 2-(2-benzimidazolyl)-5-[4-
(2-
imidazolino)phenyl]furan 
dihydrochloride 
DB00778 
 
-7.9 
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11 GALANTAMINE DB00674 
 
-6.6 
12 RIVASTIGMINE DB00989 
 
-8.7 
13 MEMANTINE DB01043  -6.5 
14 TACRINE DB00382 
 
-6.4 
15 PORPHYRIN Fe(iii) DB00382  -6.7 
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16 AMINOTHIAZOLINE DB02335 
 
-3.3 
17 ACYCLOVIR DB00787 
 
-5.6 
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CHAPTER 4 
TOXICITY RESULTS 
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4.1 TOXICITY RESULTS: 
We check the toxicity of the inhibitors by: 
Select the required molecule in .pdb and open it in Ibabel. Convert the .pdb file 
into .mol in Ibabel and save it. Now Chembioserver website was opened.  
o Open " Toxicity filtering "  
o Select the "choose file" and choose the .mol file.  
o Press " Proceed data " button below  
o Download the toxicity results file.  
 
The online server "Chembioserver" recognizes a list of organic toxic compounds. 
This server checks if the molecule contains any of organic toxic compounds. If it 
does not contain any of the organic toxic compounds, the result is PASS i.e 
Nontoxic. If it contains any toxic compounds, the result is FAIL i.e Toxic. 
                                          Figure 4.1: Website of ChemBioServer 
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Table C: Toxicity results of inhibitors docked with 1XYU and 1FO7. 
INHIBITOR RESULT LogP VALUE 
2-(2-benzimidazolyl)-5-[4-(2-
imidazolino)phenyl]furan 
dihydrochloride 
NON TOXIC 1.91 
LOVASTATIN NON TOXIC 3.79 
TERFENADINE NON TOXIC 7.18 
TACRINE NON TOXIC 2.92 
ASTEMIZOLE NON TOXIC 6.46 
GALANTAMINE TOXIC 1.69 
PENTOSAN POLYSULFATE NON TOXIC -11.17 
ACYCLOVIR NON TOXIC -1.67 
AMANTADINE NON TOXIC 1.92 
RIVASTIGMINE NON TOXIC 2.05 
MEMANTINE NON TOXIC 2.78 
CLONAZEPAM NON TOXIC 2.06 
PROMETHAZINE NON TOXIC 4.34 
QUINACRINE NON TOXIC 6.45 
PORPHYRIN Fe(iii) NON TOXIC 2.10 
AMINOTHIAZOLINE NON TOXIC 0.32 
PERK INHIBITORS NON TOXIC 4.11 
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FINAL RESULTS 
Two molecules Perk Inhibitors and Lovastatin have shown best binding results on 
docking with 1XYU and 1FO7. 
Table D: Final results: 
 PERK INHIBITORS LOVASTATIN 
CHEMICAL 
STRUCTURE 
  
PYMOL 
VISUALIZED 
STRUCTURE 
 
 
Docking result 
with 1XYU 
-12.9 kcal/mol -11.9 kcal/mol 
Docking result 
with 1FO7 
-8.5 kcal/mol -9.3 kcal/mol 
Toxicity NON TOXIC NON TOXIC 
Partition 
Coeffecient 
(LogP) value 
4.11 3.79 
Molecular 
formula 
C24 H20 F3 N5 O C24 H36 O5  
Molecular weight 451.16 g/mol 404.26 g/mol 
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Output of docking LOVASTATIN with 1FO7 and 1XYU respectively 
 
 
 
 
 
 
 
Output of docking PERK INHIBITORS with 1XYU and 1FO7 respectively 
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DISCUSSION 
Scrapie is a deadly, degenerative disease which attacks the nervous system of 
sheep and goats. It is a type of Transmissible Spongiform Encephalopathies 
(TSEs), also related to Bovine Spongiform Encephalopathies (BSEs or ―mad cow 
disease‖) and chronic wasting disease of deer[11]. A protein named PRION causes 
Spongiform Encephalopathies which include Scrapie disease[15]. 
CREUTZFELDT-JAKOB DISEASE is a degenerative neurological disorder which 
is not curable and has a high mortal rate. It is also known as the human version of 
mad cow disease even though classic CJD can’t be compared to bovine spongiform 
encephalopathy. The disease is also caused by a Prion protein. The transformation 
of the α-helical, cell isoform of the prion protein (PrPc) to the insoluble, β-sheet 
rich irresistible, malady creating isoform (PrP
sc
) is the key occasion in prion 
infection. In a prior study, a few types of PrP
c
 changing over to PrP
sc
 causes Prion 
replication. We then select two protein structures of Prion which are 1XYU and 
1FO7 from Protein Data Bank and download them in .pdb format. We then search 
for various drugs which are already available in market for Scrapie disease and 
CJD. We also look for other potential drugs which could be useful in docking with 
the two proteins. We search various literatures in order to get information about 
various inhibitors and their role in inhibiting Prion protein replication. We found 
that some anti-malarial[19] and anti-cholesterol drugs from screening of several 
drugs are useful in the process of docking[12]. We also find the active sites of the 
two proteins by the help of CASTP calculator. We could also visualize the binding 
sites present in the protein by the help of CASTP. After docking the inhibitors with 
1XYU and 1FO7, by the help of Autodock Vina 4.0, we found that inhibitors like 
Perk inhibitors, Lovastatin, Terfenadine, Quinacrine have shown better binding 
energy than others. After that we do online toxicity test on all the inhibitors and it 
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was found that Galantamine was toxic. We also calculate the Partition coefficient 
value of the inhibitors in order to predict the drug likeness. 
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CONCLUSION 
After docking various inhibitors with the proteins 1XYU and 1FO7, it was found 
that inhibitors like Quinacrine, Terfenadine, Lovastatin, Pentosan Polysulfate, 
Promethazine, Perk Inhibitors, 2-(2-benzimidazolyl)-5-[4-(2-
imidazolino)phenyl]furan dihydrochloride, Galantamine, Rivastigmine, 
Memantine and Tacrine showed higher values of affinity when docked with 
1XYU. After docking inhibitors with 1FO7, Quinacrine, Astemizole, 
Terfenadine, Lovastatin, Pentosan Polysulfate, Perk Inhibitors and 
Rivastigmine showed higher values of affinity. Toxicity tests of the inhibitors 
were done on all the inhibitors docked and all them (except GALANTAMINE) 
passed the toxicity test.  Eventually it was found that the above inhibitors proved to 
be effective in the process of inhibiting the two Prion  proteins 1XYU and 1FO7.  
  At present a huge amount of research is being done on this disease and day by 
day new inhibitors are found which are effective. Thus the future in doing research 
on this disease is quite approaching. 
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